ReviewClinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology2025
Xanomeline-trospium (Cobenfy
Review in Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Article
- Beyond dopamine blockade: mechanistic humility and the rise of muscarinic, TAAR1, and glutamatergic pathways in schizophrenia.Frontiers in psychiatry · 2026Article
- From dopamine to muscarine: xanomeline-trospium (KarXT) as a novel direction in the psychopharmacotherapy of schizophrenia.Frontiers in pharmacology · 2026Review
- Targeting disrupted networks in schizophrenia: Can muscarinic drugs make a fundamental difference?Journal of psychopharmacology (Oxford, England) · 2025Review
- Considerations for Augmenting Aripiprazole Long-Acting Injectables with Other Antipsychotics: A Mini-Review.Diseases (Basel, Switzerland) · 2025Review
- From betel nuts to Cobenfy: how an ancient recreational drug gave rise to a new class of schizophrenia medications.CNS spectrums · 2025Review
- Targeting muscarinic receptors in schizophrenia treatment: Novel antipsychotic xanomeline/trospium chloride.World journal of psychiatry · 2025Review
- Cobenfy (xanomeline-trospium): a breakthrough FDA-approved therapy redefining schizophrenia treatment.Annals of medicine and surgery (2012) · 2025Article
- [Antipsychotic drugs beyond the dopamine DDer Nervenarzt · 2025Review
- Real-world effectiveness and safety of xanomeline and trospium for treatment-resistant schizophrenia in a state hospital system.Frontiers in psychiatry · 2025Article
- Early outpatient clinical experience with xanomeline and trospium chloride for schizophrenia: a case report.Frontiers in psychiatry · 2025Article
- Novel opportunities for treating complex neuropsychiatric and neurocognitive conditions based on recent developments with xanomeline.Frontiers in psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a chronic and severe mental illness associated with substantial morbidity and mortality. Antipsychotics primarily rely on direct dopamine blockade, leading to potential life-interfering adverse events. The purpose of this review is to describe the safety and efficacy of xanomeline-trospium (Cobenfy
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.